This study aimed to investigate whether the classic hepatoprotective drug polyene phosphatidylcholine (PPC) regulates macrophage polarization and explores the potential role of TLR-2 in this process. In RAW264.7 macrophages and murine bone marrow-derived macrophages (BMDMs) stimulated by lipopolysaccharide (LPS), PPC significantly inhibited the production of IL-6, TNF-α, and the mRNA expression of M1-type macrophage markers. Consistently, PPC reduced the mRNA expression of several key enzymes in the pathways of glycolysis and lipid synthesis while increasing the expression of key enzymes associated with lipid oxidation. Moreover, blocking the glycolytic pathway using 2-deoxy-D-glucose (2-DG) significantly enhanced the anti-inflammatory effect of PPC. However, inhibition of lipid oxidation using GW9662 (an inhibitor of PPAR-γ) and GW6471 (an inhibitor of PPAR-α) abolished the anti-inflammatory effect of PPC. Interestingly, TLR-2 expression in macrophages was significantly downregulated after exposure to PPC. Moreover, pre-activation of TLR-2 hampered the anti-inflammatory effect of PPC. In addition, PPC did not inhibit the secretion of IL-6 and TNF-α in TLR-2 BMDMs that were activated by LPS. This was consistent with the increased expression of M1 markers and glycolytic and lipid synthesis enzymes but decreased lipid oxidation-related enzymes. These results showed that PPC inhibits the differentiation of M1-type macrophages, which was most likely related to TLR-2-mediated metabolic reprogramming.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12026-020-09125-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biologics Used for Psoriasis: A Drug Utilization Study Based on Two Nationwide Danish Data Sources.
Pharmacoepidemiol Drug Saf
November 2024
Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Article Synopsis
- Biological treatment has significantly improved the management of moderate-to-severe psoriasis in Denmark, with two main data sources being used to explore its utilization.
- Between 2011 and 2018, 1878 users were identified in healthcare registries and 2264 in the Dermbio database, with Adalimumab, Ustekinumab, and Secukinumab being the most commonly prescribed first treatments.
- Ustekinumab demonstrated the longest duration of effectiveness across both data sources, highlighting important differences in treatment patterns and drug survival rates that researchers should consider in future studies.
Polyenylphosphatidylcholine alleviates cardiorenal fibrosis, injury and dysfunction in spontaneously hypertensive rats by regulating Plpp3 signaling.
Front Cardiovasc Med
September 2024
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.
Objective: Polyenylphosphatidylcholine (PPC), a significant therapeutic agent for liver repair, exhibits potent antioxidant and anti-inflammatory properties. Nonetheless, its impact on hypertension and hypertensive vascular diseases requires clarification. Our objective was to elucidate the protective role and mechanism of PPC in a spontaneously hypertensive rat model.
View Article and Find Full Text PDFEmergency Department Use of Heart Failure-Exacerbating Medications in Patients with Chronic Heart Failure.
Drug Saf
December 2024
Department of Emergency Medicine, University of North Carolina School of Medicine, 170 Manning Dr, CB# 7594, Chapel Hill, NC, 27599-7594, USA.
Article Synopsis
- Heart failure-exacerbating medications (HFEMs) are frequently used in patients with heart failure (HF) during emergency department (ED) visits, leading to potential preventable heart failure episodes.
- An observational study analyzed 23,907 ED encounters from 2016 to 2020, revealing that 20% of these encounters involved the administration or prescription of HFEMs, with higher rates of administration in the ED compared to prescriptions at discharge.
- The most commonly used HFEMs included nonsteroidal anti-inflammatory drugs (11%) and albuterol (7%), indicating a need for improved medication management for HF patients in the ED.
[Establishment of an Engineered Bacterial Membrane Biomimetic Nanodrug Delivery System and Its Role in the Treatment of Glioma].
Sichuan Da Xue Xue Bao Yi Xue Ban
July 2024
（ 471099） Luoyang Vocational and Technical College, Luoyang 471099, China.
Article Synopsis
- The study aims to create engineered bacterial membrane biomimetic nanoparticles (ANG-2 EM@PPC) for targeted drug delivery in glioma treatment, seeking to enhance therapy efficiency.
- Methodologies include creating engineered bacteria, preparing nanoparticles, and utilizing various techniques like Western blotting and flow cytometry to analyze their effectiveness in targeting glioma cells.
- Animal experiments involved a glioma mouse model to assess the impact of different nanoparticle formulations on tumor distribution and therapeutic potential.
- Complex Alleviates Alcoholic Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation: A Transcriptome and Gut Microbiota Analysis.
Foods
August 2024
School of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, China.
Background: Lipid metabolism disorder appears to be one of the early features of alcoholic liver disease (ALD), which can be speculated via omics analysis including liver transcriptomics and gut microbiota. A complex consisting of the roots of and dried fruits of (PPC), which possesses hepatoprotective effects, could serve as a drug or functional food. The lack of non-polysaccharide compounds in PPC with their moderation effects on gut microbiota suggests the necessity for a relevant study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!